Company intelligence / Profile preview

Synthonics, Inc.

Blacksburg, Virginia, United Statessynthonicsinc.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Synthonics has developed several metal-coordinated pharmaceuticals including zinc-T3 and magnesium-furosemide complexes. They've also worked with RS BioTherapeutics on RSBT-001, a nebulized, semi-synthetic cannabidiolic acid complex for pulmonary inflammation, which showed positive results in a proof-of-concept study[3].

Therapeutic areas: GastroenterologyPulmonologyEndocrinologyOncologyNeurologyInfectious Diseases
Modalities: Metal Coordinated Pharmaceuticals (MCPs)
Industry: Biotech

Drug pipeline

3 assets

Chylobinoid

2 more assets in the full pipeline.

Request access →

Partnerships

RS BioTherapeuticsMarshall University

Beyond the preview

Go deeper on Synthonics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synthonics, Inc..

Explore the full profile